Clinical Trial Update: MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating MK0249 for symptomatic treatment of Alzheimer's disease has completed. The results were posted in November 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• MK0249

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED | Results posted: 2010-11-18